Loss of osteopontin perturbs the epithelial-mesenchymal transition in an injured mouse lens epithelium

Laboratory Investigation

Volumn 87, Issue 2, 2007, Pages 130-138

  Saika, Shizuya ^a   Shirai, Kumi ^a   Yamanaka, Osamu ^a   Miyazaki, Ken Ichi ^a   Okada, Yuka ^a   Kitano, Ai ^a   Flanders, Kathleen C ^b   Kon, Shigeyuki ^c   Uede, Toshimitsu ^c   Kao, Winston Whei Yang ^d   Rittling, Susan R ^e   Denhardt, David T ^e   Ohnishi, Yoshitaka ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HOKKAIDO UNIVERSITY   (Japan)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

Epithelial mesenchymal transition; Lens epithelium; Osteopontin; Smad; Wound healing

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BIOLOGICAL MARKER; COLLAGEN TYPE 1; OSTEOPONTIN; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; EXPERIMENTAL STUDY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LENS; LENS EPITHELIUM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PUNCTURE; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; WOUND HEALING;

ACTINS; ANIMALS; BROMODEOXYURIDINE; CELL ADHESION; COLLAGEN TYPE I; EPITHELIAL CELLS; IMMUNOHISTOCHEMISTRY; LENS, CRYSTALLINE; MESODERM; MICE; MICE, KNOCKOUT; OSTEOPONTIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; WOUND HEALING;

EID: 33847194696     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700508     Document Type: Article

References (51)

1. Hay ED, Zuk A. Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am J Kidney Dis 1995;26:678-690.
2. Roberts AB, Tian F, Byfield SD, et al. Smad3 is key to TGF-β-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006;17:19-27.
3. Saika S, Kawashima Y, Miyamoto T, et al. Immunolocalization of prolyl 4-hydroxylase subunits, a-smooth muscle actin, and extracellular matrix components in human lens capsules with lens implants. Exp Eye Res 1998;66:283-294.
4. Saika S, Okada Y, Miyamoto T, et al. Smad translocation and growth suppression in lens epithelial cells by endogenous TGFβ2 during wound repair. Exp Eye Res 2001;72:679-686.
5. Meacock WR, Spalton DJ, Stanford MR. Role of cytokines in the pathogenesis of posterior capsule opacification. Br J Ophthalmol 2000;84:332-336.
6. Wormstone IM. Posterior capsular opacification: a cell biological perspective. Exp Eye Res 2002;74:337-347.
7. Saika S. Relationship between posterior capsule opacification and intraocular lens biocompatibility. Prog Retin Eye Res 2004;23:283-305.
8. Serini G, Bochaton-Piallat M-L, Ropraz P, et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1. J Cell Biol 1998;142:873-881.
9. Serini G, Gabbiani G. Mechanism of myofibroblast activity and phenotypic modulation. Exp Cell Res 1999;250:273-283.
10. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechanoregulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3:349-363.
11. Saika S, Miyamoto T, Tanaka T, et al. Latent TGFβ binding protein-1 and fibrillin-1 in human capsular opacification and in cultured lens epithelial cells. Br J Ophthalmol 2001;85:1362-1366.
12. Miettinen PJ, Ebner R, Lopez AR, et al. TGF-β induced transdifferenttiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994;127:2021-2036.
13. Srinivasan Y, Lovicu FJ, Overbeek PA. Lens specific expression of transforming growth factor β1 in transgenic mice causes anterior subcapsular cataracts. J Clin Invest 1998;101:625-634.
14. Lee EH, Joo C-K. Role of transforming growth factor-β in transdifferentiation and fibrosis of lens epithelial cells. Invest Ophthalmol Vis Sci 1999;40:2025-2032.
15. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nature Cell Biol 2002;4:487-494.
16. Wormstone IM, Tamiya S, Andersone I, et al. TGF-β2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci 2002;43:2301-2308.
17. Saika S, Kono-Saika S, Ohnishi Y, et al. Smad3 signaling is required for epithelial-mesenchymal transition of lens epithelium after injury. Am J Pathol 2004;164:651-663.
18. Saika S. TGFβ pathobiology in the eye. Lab Invest 2006;86:106-115.
19. Hay ED. Extracellular matrix alters epithelial differentiation. Curr Opin Cell Biol 1989;14:455-457.
20. Zuk A, Hay ED. Expression of β1 integrins changes during transformation of avian lens epithelium to mesenchyme in collagen gels. Dev Dyn 1994;201:378-393.
21. Saika S, Miyamoto T, Tanaka S, et al. Response of lens epithelial cells to injury: role of lumican in epithelial-mesenchymal transition. Invest Ophthalmol Vis Sci 2003;44:2094-2102.
22. Zeisberg M, Bonner G, Maeshima Y, et al. Collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 2001;159:1313-1321.
23. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type I (cell-mediated) immunity. Science 2000;287:860-864.
24. O'Regan AW, Nau GJ, Chupp GL, et al. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 2000;21:475-478.
25. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001;294:1731-1735.
26. Denhardt DT, Noda M, O'Regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-1061.
27. Gravallese EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest 2003;112:147-149 (Review). Erratum in: J Clin Invest. 2003;112:627.
28. O'Regan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev 2003;14:479-488.
29. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 2004;26:179-184.
30. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006;16:79-87.
31. Saika S, Miyamoto T, Ishida I, et al. Osteopontin: a component of matrix in capsular opacification and subcapsular cataract. Invest Ophthalmol Vis Sci 2003;44:1622-1628.
32. Jampel HD, Roche N, Stark WJ, et al. Transforming growth factor-beta in human aqueous humor. Curr Eye Res 1990;9:963-969.
33. Cousins SW, McCabe MM, Danielpour D, et al. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci 199;32:2201-2211.
34. Saika S, Saika S, Liu CY, et al. TGFβ2 in corneal morphogenesis during mouse embryonic development. Dev Biol 2001;240:419-432.
35. Saika S, Ikeda K, Yamanaka O, et al. Transient adenoviral gene transfer of Smad7 prevents injury-induced epithelial-mesenchymal transition of lens epithelium in mice. Lab Invest 2004;84:1259-1270.
36. Berman JS, Serlin D, Li X, et al. Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice. Am J Physiol Lung Cell Mol Physiol 2004;286:L1311-L1318.
37. Gadeau AP, Campan M, Millet D, et al. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb 1993;13:120-125.
38. Gardner HA, Berse B, Senger DR. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene 1994;9:2321-2326.
39. Ashizawa N, Graf K, Do YS, et al. Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction. J Clin Invest 1996;98:2218-2227.
40. Liaw L, Birk D, Ballas C, et al. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J Clin Invest 1998;101:1468-1478.
41. Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999;56:571-580.
42. Trueblood NA, Xie Z, Communal C, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 2001;88:1080-1087.
43. Lee SH, Seo GS, Park YN, et al. Effects and regulation of osteopontin in rat hepatic stellate cells. Biochem Pharmacol 2004;68:2367-2378.
44. Lorena D, Darby IA, Gadeau AP, et al. Osteopontin expression in normal and fibrotic liver. altered liver healing in osteopontin-deficient mice. J Hepatol 2006;44:383-390.
45. Saika S, Kono-Saika S, Tanaka T, et al. Smad3 is required for dedifferentiation of retinal pigment epithelium following retinal detachment in mice. Lab Invest 2004;84:1245-1258.
46. Tran KT, Griffith L, Wells A. Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen 2004;12:262-268.
47. Duca L, Floquet N, Alix AJ, et al. Elastin as a matrikine. Crit Rev Oncol Hematol 2004;49:235-244.
48. Tran KT, Lamb P, Deng JS. Matrikines and matricryptins: Implications for cutaneous cancers and skin repair. J Dermatol Sci 2005;40:11-20.
49. Iozzo RV. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J Clin Invest 2001;108:165-167.
50. Saika S, Shiraishi A, Liu CY, et al. Role of lumican in the corneal epithelium during wound healing. J Biol Chem 2000;275:2607-2612.
51. Carlson EC, Liu CY, Chikama T, et al. Keratocan, a cornea-specific keratan sulfate proteoglycan, is regulated by lumican. J Biol Chem 2005;280:25541-25547.